Effects of peripheral administration of synthetic human glucose-dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes

Clinical Endocrinology

Volumn 71, Issue 2, 2009, Pages 195-201

  Daousi, C ^a   Wilding, J P H ^a   Aditya, S ^a   Durham, B H ^b   Cleator, J ^a   Pinkney, J H ^a,c   Ranganath, L R ^b  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^c ROYAL CORNWALL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; PLACEBO;

ADULT; APPETITE; ARTICLE; BODY WEIGHT; CALORIC INTAKE; CALORIE; CALORIMETRY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENERGY BALANCE; ENERGY EXPENDITURE; FOOD INTAKE; HUMAN; HUNGER; INSULIN LIKE ACTIVITY; INSULIN RELEASE; MACRONUTRIENT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VISUAL ANALOG SCALE;

ADMINISTRATION, TOPICAL; ADULT; APPETITE; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; GASTRIC INHIBITORY POLYPEPTIDE; HUMANS; MALE; MIDDLE AGED; TASTE;

EID: 67650340423     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2008.03451.x     Document Type: Article

References (31)

1. Hansotia, T., Maida, A., Flock, G. et al. (2007) Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. Journal of Clinical Investigation, 117, 143 152. (Pubitemid 46048461)
2. Hansotia, T. Drucker, D.J. (2005) GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice. Regulatory Peptides, 128, 125 134. (Pubitemid 40380913)
3. Yamada, Y. Seino, Y. (2004) Physiology of GIP - a lesson from GIP receptor knockout mice. Hormone and Metabolic Research, 36, 771 774. (Pubitemid 40115898)
4. Yamada, Y., Miyawaki, K., Tsukiyama, K. et al. (2006) Pancreatic and extrapancreatic effects of gastric inhibitory polypeptide. Diabetes, 55, S86 S91.
5. Nauck, M., Stockmann, F., Ebert, R. et al. (1986) Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia, 29, 46 52. (Pubitemid 16162741)
6. Holst, J.J. Gromada, J. (2004) Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. American Journal of Physiology. Endocrinology and Metabolism, 287, E199 E206.
7. Meier, J.J., Nauck, M.A., Schmidt, W.E. et al. (2002) Gastric inhibitory polypeptide: the neglected incretin revisited. Regulatory Peptides, 107, 1 13. (Pubitemid 34876440)
8. Vilsboll, T., Knop, F.K., Krarup, T. et al. (2003) The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. Journal of Clinical Endocrinology and Metabolism, 88, 4897 4903. (Pubitemid 37357541)
9. Nauck, M.A., Heimesaat, M.M., Orskov, C. et al. (1993) Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. Journal of Clinical Investigation, 91, 301 307. (Pubitemid 23037285)
10. Nauck, M.A., Baller, B. Meier, J.J. (2004) Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Diabetes, 53, S190 S196.
11. Meier, J.J., Gallwitz, B., Kask, B. et al. (2004) Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects. Diabetes, 53, S220 S224.
12. Vilsboll, T., Krarup, T., Madsbad, S. et al. (2002) Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia, 45, 1111 1119. (Pubitemid 34985287)
13. Nauck, M.A., Bartels, E., Orskov, C. et al. (1993) Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. Journal of Clinical Endocrinology and Metabolism, 76, 912 917.
14. Elahi, D., oon-Dyke, M., Fukagawa, N.K. et al. (1994) The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regulatory Peptides, 51, 63 74. (Pubitemid 24119981)
15. Meier, J.J., Gallwitz, B., Siepmann, N. et al. (2003) Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia, 46, 798 801. (Pubitemid 36831408)
16. Shalev, A., Holst, J.J. Keller, U. (1997) Effects of glucagon-like peptide 1 (7-36 amide) on whole-body protein metabolism in healthy man. European Journal of Clinical Investigation, 27, 10 16. (Pubitemid 27065167)
17. Jones, K.L., Berry, M., Kong, M.F. et al. (1999) European journal of clinical investigation the gastrokinetic effect of erythromycin and affects the perception of postprandial hunger in normal subjects. Diabetes Care, 22, 339 344. (Pubitemid 29056932)
18. Andrews, J.M., Rayner, C.K., Doran, S. et al. (1998) Physiological changes in blood glucose affect appetite and pyloric motility during intraduodenal lipid infusion. American Journal of Physiology, 275, G797 G804.
19. Russell, A.W., Horowitz, M., Ritz, M. et al. (2001) The effect of acute hyperglycaemia on appetite and food intake in Type 1 diabetes mellitus. Diabetic Medicine, 18, 718 725. (Pubitemid 32955523)
20. Turton, M.D., O'Shea, D., Gunn, I. et al. (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. Nature, 379, 69 72. (Pubitemid 26008136)
21. Tang-Christensen, M., Larsen, P.J., Goke, R. et al 1996) Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. American Journal of Physiology, 271, R848 R856.
22. Flint, A., Raben, A., Astrup, A. et al. (1998) Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. Journal of Clinical Investigation, 101, 515 520. (Pubitemid 28084232)
23. Gutzwiller, J.P., Goke, B., Drewe, J. et al. (1999) Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut, 44, 81 86. (Pubitemid 29143284)
24. Gutzwiller, J.P., Drewe, J., Goke, B. et al. (1999) Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. American Journal of Physiology, 276, R1541 R1544.
25. Naslund, E., Barkeling, B., King, N. et al. 1999) Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. International Journal of Obesity and Related Metabolic Disorders, 23, 304 311. (Pubitemid 29118862)
26. Toft-Nielsen, M.B., Madsbad, S. Holst, J.J. (1999) Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care, 22, 1137 1143. (Pubitemid 29293967)
27. Flint, A., Raben, A., Ersboll, A.K. et al. (2001) The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. International Journal of Obesity and Related Metabolic Disorders, 25, 781 792. (Pubitemid 32601369)
28. Long, S.J., Sutton, J.A., Amaee, W.B. et al. (1999) No effect of glucagon-like peptide-1 on short-term satiety and energy intake in man. The British Journal of Nutrition, 81, 273 279. (Pubitemid 29248498)
29. Naslund, E., Gutniak, M., Skogar, S. et al. (1998) Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. American Journal of Clinical Nutrition, 68, 525 530. (Pubitemid 28402372)
30. Meier, J.J., Goetze, O., Anstipp, J. et al. (2004) Gastric inhibitory polypeptide does not inhibit gastric emptying in humans. American Journal of Physiology. Endocrinology and Metabolism, 286, E621 E625.
31. Verdich, C., Flint, A., Gutzwiller, J.P. et al. (2001) A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. Journal of Clinical Endocrinology and Metabolism, 86, 4382 4389. (Pubitemid 32848563)